Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02769299 · ClinicalTrials.gov registry record
Cardiotoxicity of Radiation Therapy (CTRT)
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 147
- Enrollment target
NCT02769299: Completed study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02769299 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 147 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02769299 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 147 participants
- Enrollment target
Study Summary
The overall objective of this proposal is to determine the utility of sensitive imaging and biomarker measures in detecting subclinical cardiotoxicity across a spectrum of radiation doses to the heart. We will focus specifically on patients receiving photon or proton chest radiotherapy. Our broad working hypothesis is that RT induces early, subclinical CV injury, as evidenced by cardiomyocyte inflammation and necrosis, and worsening CV function.
Interventions
- RADIATION Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2015-06-02 |
| Est. Completion | 2018-11-26 |
What the finished NCT02769299 record still lists
NCT02769299 is an observational study that tracks outcomes without assigning an intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Radiation Therapy is the first listed.
NCT02769299 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02769299 about?
NCT02769299 is a clinical study titled "Cardiotoxicity of Radiation Therapy (CTRT)". The overall objective of this proposal is to determine the utility of sensitive imaging and biomarker measures in detecting subclinical cardiotoxicity across a spectrum of radiation doses to the heart. We will focus specifically on patients receiving photon or proton chest radiotherapy. Our broad wo...
What is the current status of trial NCT02769299?
This trial is currently completed. The enrollment target is 147 participants. The study started on 2015-06-02. Estimated completion is 2018-11-26.
What interventions are being tested in trial NCT02769299?
The interventions under investigation include: Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT02769299?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI